Merck has once again failed to boost the effects of its PD-1 blockbuster Keytruda by adding AstraZeneca’s PARP inhibitor Lynparza.
When given as a maintenance therapy, Lynparza and Keytruda did not result in survival benefits for certain first-line nonsquamous non-small cell lung cancer (NSCLC) patients compared to Keytruda and pemetrexed, a type of chemotherapy. The combo also failed to meet its second primary endpoint, progression-free survival, Merck announced Thursday.
This marks the latest in a string of failures for Keytruda and Lynparza, including a study in squamous NSCLC that was stopped in December when interim analyses failed to show meaningful improvements in overall and progression-free survival. Another combo study was stopped in March 2022 in metastatic castration-resistant prostate cancer (mCRPC) after also failing to show benefits in OS and PFS.
Merck said Thursday that it’s conducting a “full evaluation” of the study. The company reported safety results consistent with prior studies for the individual therapies. As of press time, Merck did not respond to questions about whether it will continue to pursue a combination approach in NSCLC.
“As lung cancer continues to be the leading cause of cancer death worldwide, we are committed to exploring KEYTRUDA-based combinations and novel candidates that may further help improve patient outcomes,” Merck Research Laboratories VP of Global Clinical Development Gregory Lubiniecki said in a news release.
CLICK HERE TO CONTINUE READING
- Forums
- ASX - By Stock
- IMM
- Media
Media, page-665
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
39.3¢ |
Change
-0.003(0.63%) |
Mkt cap ! $573.7M |
Open | High | Low | Value | Volume |
39.0¢ | 39.8¢ | 39.0¢ | $152.9K | 387.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
30 | 121653 | 39.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.5¢ | 76311 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
30 | 121653 | 0.390 |
12 | 107283 | 0.385 |
12 | 83776 | 0.380 |
8 | 58610 | 0.375 |
7 | 97156 | 0.370 |
Price($) | Vol. | No. |
---|---|---|
0.395 | 76311 | 17 |
0.400 | 116083 | 13 |
0.405 | 251190 | 9 |
0.410 | 269385 | 12 |
0.415 | 200197 | 11 |
Last trade - 11.25am 06/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |